cabergoline has been researched along with metyrapone in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Schteingart, DE | 1 |
Barahona Constanzo, MJ; del Pozo Picó, C | 1 |
Gadelha, MR; Vieira Neto, L | 1 |
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
Biller, BMK; Tritos, NA | 1 |
Boguszewski, CL; Marques, JVO | 1 |
6 review(s) available for cabergoline and metyrapone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drugs in the medical treatment of Cushing's syndrome.
Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Antiparkinson Agents; Cabergoline; Cushing Syndrome; Ergolines; Human Growth Hormone; Humans; Hydrocortisone; Ketoconazole; Metyrapone; Pituitary Hormones; Pituitary Neoplasms | 2009 |
New prospects for drug treatment in Cushing disease.
Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin | 2012 |
Efficacy of medical treatment in Cushing's disease: a systematic review.
Topics: Cabergoline; Ergolines; Female; Humans; Ketoconazole; Male; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin | 2014 |
Medical Management of Cushing Disease.
Topics: Cabergoline; Etomidate; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Temozolomide; Treatment Outcome | 2019 |
Medical therapy in severe hypercortisolism.
Topics: Cabergoline; Cushing Syndrome; Humans; Ketoconazole; Metyrapone; Mitotane | 2021 |
1 other study(ies) available for cabergoline and metyrapone
Article | Year |
---|---|
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |